Valsartan: Nursing Drug Guide, Fetal Toxicity & Hold Rules
Diovan blocks angiotensin II at the AT1 receptor for hypertension, heart failure, and post–myocardial infarction care—but the boxed fetal toxicity warning means nurses must stop therapy as soon as pregnancy is detected. On every shift, also track hyperkalemia, creatinine trends, and symptomatic hypotension when diuretics, NSAIDs, or potassium-raising drugs overlap.
The Diovan boxed warning states that when pregnancy is detected, valsartan should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Labeling also warns about symptomatic hypotension in volume- or salt-depleted patients (often on diuretics), renal function deterioration, and hyperkalemia—especially with potassium-raising drugs or dual RAS blockade. Angioedema has been reported rarely with valsartan, including in patients with prior ACE inhibitor angioedema; discontinue and escalate airway care when breathing is threatened.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every valsartan dose, reconcile pregnancy status, airway-threatening swelling, and whether a new diuretic or NSAID could trigger symptomatic hypotension or a creatinine/potassium jump—Diovan labeling emphasizes supervised first doses when diuretics cannot be stopped.
Most common brand names
Valsartan is an angiotensin II receptor blocker (ARB). The reference U.S. brand is Diovan (40 mg scored, 80 mg, 160 mg, and 320 mg tablets). Fixed combinations with hydrochlorothiazide or sacubitril/valsartan (Entresto) are common—confirm every ingredient on the order. Pharmacy may compound an oral suspension from tablets per manufacturer directions. Trace every product through medication reconciliation rather than relying on look-alike labels.
Why we give it — Indications
Valsartan tablet prescribing information (Diovan) approves valsartan for hypertension in adults and, on some labels, pediatric patients from 1 year of age, for heart failure (NYHA class II–IV) to reduce hospitalization in adults, and for clinically stable adults after myocardial infarction with left ventricular failure or dysfunction to reduce cardiovascular mortality. Nurses on cardiac and medical–surgical units give once-daily hypertension doses or divided heart-failure and post-MI regimens while watching potassium and creatinine trends.
Pediatric age limits vary by product and formulation. Some current valsartan labels include hypertension use in children 1 year and older (often with dosing established for ages 1–16 years), while some tablet labels state use is not recommended under 6 years. Verify the exact dispensed product label and local formulary before applying pediatric dosing.
| Use | Detail |
|---|---|
| Hypertension | Lowers blood pressure in adults; pediatric limits vary by label (some products from 1 year, some not recommended <6 years)—verify product PI before pediatric use; usual adult start 80 or 160 mg once daily (range 80–320 mg/day). |
| Heart failure | Reduces hospitalization for heart failure (NYHA II–IV); start 40 mg twice daily, titrate to 80–160 mg twice daily (max 320 mg/day divided). |
| Post–myocardial infarction | May start as early as 12 h post-MI; start 20 mg twice daily, titrate toward 160 mg twice daily as tolerated for LV failure/dysfunction. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Valsartan selectively blocks the AT1 angiotensin II receptor, reducing vasoconstriction and aldosterone-mediated sodium retention without inhibiting ACE directly. Valsartan is the primary active drug—no major active metabolite drives the effect. Patients switching from an ACE inhibitor often report less dry cough, but postmarketing angioedema still occurs and valsartan must not be re-administered after angioedema. Reduced aldosterone activity can raise serum potassium and worsen renal perfusion when volume is depleted—core reasons for pregnancy screening, electrolyte review, and blood pressure measurement on shift.
Dosing overview
Doses below reflect the reviewed valsartan tablet label; titrate to prescriber orders, blood pressure response, and renal-electrolyte trends. Track eGFR with serum creatinine on the basic metabolic panel.
Missed dose: Not specified in the reviewed prescribing information for a universal rule—follow prescriber guidance and institutional protocol; do not double doses.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption / onset | Peak plasma concentration 2–4 h after dosing; antihypertensive effect substantially present within ~2 weeks, maximal reduction generally ~4 weeks | Monitor for hypotension when volume-depleted even before maximal BP lowering |
| Half-life / bioavailability | Elimination half-life ~6 h; absolute bioavailability ~25% (10–35%); suspension bioavailability ~1.6× tablet per label | Steady daily timing matters; compounded suspension only per pharmacy directions |
| Elimination | Renal insufficiency: exposure does not correlate clearly with creatinine clearance down to ~10 mL/min; valsartan is not removed by hemodialysis (overdosage) | Severe renal impairment (GFR <30) not established—monitor closely; no dialysis removal in overdose |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm pregnancy status or reliable contraception in patients of reproductive potential—use pregnancy testing per protocol and discontinue immediately if pregnancy is detected or suspected
- Review baseline and trended serum creatinine, eGFR, and potassium—especially with diabetes, dehydration, or concurrent nephrotoxic drugs
- Assess volume status and recent diuretic changes; symptomatic hypotension risk rises when salt or volume depletion is present
- Screen medication lists for NSAIDs, potassium supplements, potassium-sparing diuretics (e.g. spironolactone), other RAS agents (lisinopril, enalapril), and aliskiren combinations
Contraindications (FDA label summary)
- Hypersensitivity to any component of valsartan potassium tablets
- Coadministration with aliskiren in patients with diabetes
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| Loop diuretics, thiazide diuretics | Symptomatic hypotension when volume- or salt-depleted; correct depletion before valsartan per label | Take orthostatic vitals closely first two weeks and after dose tweaks; escalate symptomatic hypotension or oliguria |
| Potassium-retaining therapies | Agents raising serum potassium may cause hyperkalemia—monitor potassium per label | Ensure scheduled laboratory follow-up potassium review; withhold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact |
| NSAID / COX-2 inhibitors | Reduced antihypertensive effect plus worsened renal impairment risk | Educate OTC avoidance without prescriber review; monitor creatinine and blood pressure pairing when unavoidable short courses emerge |
| Dual RAS inhibition | Higher renal dysfunction hypotension potassium disturbances | Increased risk of hypotension, syncope, hyperkalemia, and renal impairment—avoid routine dual RAS blockade; VA NEPHRON-D trial cited in label |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or pharmacy-compounded suspension (per manufacturer directions in labeling).
- Valsartan tablets: 40 mg (scored), 80 mg, 160 mg, and 320 mg; swallow intact unless pharmacy directs otherwise
- May be taken with or without food; maintain a consistent daily schedule for blood pressure trending
- Suspension prepared from tablets must be refrigerated 2–8 °C, shaken before each dose, and used within compounding stability window per label—administer only pharmacy-prepared suspension
- Do not confuse valsartan with look-alike antihypertensives (see LASA section)
Expected therapeutic response
- Antihypertensive effect is substantially present within about 2 weeks; maximal reduction generally attained after about 4 weeks
- In heart failure, reduced hospitalization for heart failure was the primary outcome studied in labeling
- Patients should report improved blood pressure readings at home or clinic once volume status is stable and hypotension symptoms absent
Red flags — Stop and act
Escalate immediately when these cues appear during valsartan therapy:
- Pregnancy detected or reliably suspected—hold valsartan and notify prescriber for urgent obstetric/medication review
- Lip, tongue, or facial swelling with voice change or inspiratory difficulty—rare valsartan angioedema can obstruct the airway
- Symptomatic hypotension, syncope, or collapse—especially after diuretic intensification or dehydration
- Rapidly rising potassium or creatinine, oliguria, or nausea with renal trajectory suggesting acute kidney injury
- Signs of hyperkalemia (weakness, palpitations, ECG changes per protocol) when potassium-sparing drugs or supplements overlap
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dizziness, headache, viral infection, fatigue, abdominal pain | Hypertension trials: most common adverse reactions include headache, dizziness, viral infection, fatigue, and abdominal pain (≥2% and more common than placebo per label) | Teach orthostatic caution; distinguish nuisance symptoms from hypotension or angioedema |
| Hypotension, hyperkalemia, renal effects | Heart failure trials: dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue, and hyperkalemia among common reactions; post-MI discontinuations include hypotension and increased creatinine | Monitor BP, potassium, creatinine; hold and notify when clinically significant deterioration |
| Angioedema, hypersensitivity (postmarketing) | Angioedema reported; some patients had prior ACE inhibitor angioedema—do not re-administer valsartan; hypersensitivity and anaphylactic reactions reported | Discontinue at first airway-threatening swelling; escalate allergy/renal evaluation for vasculitis cues |
On a small screen, swipe or scroll sideways to see the full table.
Overdose management
Human valsartan overdosage data are limited in labeling. Animal lethality occurred at very high oral doses. The most likely human manifestation is hypotension; there is no specific reversal agent cited.
Recommended supportive therapies (label)
- Intravenous normal saline infusion for hypotension
- Valsartanat may be removed by hemodialysis; peritoneal dialysis removed valsartan from neonatal circulation in labeling examples
- Supportive perfusion, airway, and electrolyte monitoring per institutional toxicology protocol
- Consult local poison control / toxicology services per facility protocol when ingestion amount or intent is uncertain
Consult local poisoning or toxicology services per institutional policy when intentional overdose ingestion volume remains uncertain—even though labeling describes no reversal agent analogous to opioids or acetaminophen pathways.
Look-alike / sound-alike and error prevention
- Valsartan versus losartan / lisinopril / valacyclovir / valproate: “val-” prefixes and ARB/ACE names collide—barcode every dose and read brand and generic on the label
- Valsartan versus valsartan–HCTZ or sacubitril/valsartan (Entresto): verify monotherapy versus combination products to avoid duplicate RAS blockade
- Strength selection: 40 mg, 80 mg, 160 mg, and 320 mg tablets sit near each other in ADCs—witness high-strength pulls
- Divided dosing: heart failure and post-MI regimens use twice-daily dosing—do not substitute once-daily hypertension tablets without prescriber order
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Swallow intact | Standard Diovan tablets are intended orally intact; compounded suspension exists only via pharmacy-specific preparation—not ad hoc crushed tablets unless pharmacy validates stability. |
| Meal pairing | Eating shifts active metabolite peak latency without prohibiting coexistence consistent meals—steady daily pattern assists timing vitals trending. |
| Orthostatics | Volume-depleted hospitalized patients merit lying-standing blood pressure coupling during initial therapy weeks aligning warning language. |
| Airway adjunct readiness | Because angioedema may involve laryngeal structures rapidly, bedside teams benefit confirming emergency airway equipment availability zones when initiating new RAS inhibitor courses high-risk phenotype. |
| Pharmacy escalation triggers | Uncertainty about breastfeeding safety neprilysin transition windows lithium co-therapy dosing or suspension compounding should route through pharmacist corroboration before administration finishes. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Discontinue as soon as pregnancy is detected. Second- and third-trimester RAS exposure can reduce fetal renal function, cause oligohydramnios-related lung hypoplasia and skeletal deformations, and neonatal hypotension, anuria, or renal failure per label. |
| Chronic kidney disease / renovascular risk | Renal artery stenosis, severe heart failure, or volume depletion may predispose to acute renal failure on valsartan—monitor renal function periodically and consider withholding or discontinuing when clinically significant decline occurs. |
| Pediatrics | Pediatric age limits vary by valsartan product—verify label before dosing. When permitted (e.g., Diovan 1–16 years): start 1 mg/kg once daily (up to 40 mg); may use 2 mg/kg; max 4 mg/kg (160 mg/day). Some tablet labels not recommended <6 years. Severe renal impairment (GFR <30) not established per label. |
| Black ancestry monotherapy caveat | LIFE study subgroup: Black patients with LVH on atenolol (+HCTZ background) had different composite CV outcomes than those on valsartan—interpretation limited; ensure individualized prescribing and monitoring per clinician—not a nursing hold criterion alone. |
| Lactation | LactMed cites low breastmilk concentrations with modeled infant ingestion under 0.14% maternal weight-adjusted doses predominantly active metabolite whose oral bioavailability clinically trivial—overall infant risk expectation low individualized discussion remains standard. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness—complete orthostatic blood pressure sets when diuretics overlap; labeling warns about symptomatic hypotension with volume depletion
- Serum creatinine, eGFR, and electrolyte trends—including potassium—per prescriber and institutional protocol
- Orthostatic blood pressure when diuretics overlap or after illness-related dehydration
- Signs of angioedema or anaphylaxis—especially in patients with prior ACE inhibitor angioedema
Document
- Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
- Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and OTC NSAID/potassium supplement use
- Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends
Patient teaching
- Report possible pregnancy immediately—valsartan must be stopped as soon as pregnancy is detected per boxed warning
- Facial, lip, tongue, or throat swelling, hoarseness, or trouble breathing means stop the drug and seek emergency care—do not take another dose
- Do not start potassium supplements, salt substitutes, or potassium-sparing diuretics without prescriber approval
- Report dizziness, fainting, vomiting, diarrhea, or reduced fluid intake—volume loss raises hypotension risk with ARBs
- Check with the care team before OTC NSAIDs—combined use can worsen kidneys and blunt blood pressure control per labeling
- Take valsartan at the same time each day; do not double doses if one is missed—follow prescriber or pharmacist instructions
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Pregnancy confirmed or suspected—discontinue immediately and notify prescriber for obstetric follow-up
- Angioedema or airway-threatening swelling of face, lips, tongue, or throat—hold and escalate per emergency protocol
- Hyperkalemia per institutional critical value, symptomatic hypotension, syncope, or shock until volume status reviewed
- Oliguria or clinically significant creatinine rise after dehydration, NSAID use, or dual RAS-blocking therapy
- Order conflicts: valsartan with aliskiren in diabetes, or prohibited dual RAS blockade per facility policy—clarify before administering
Clinical practice integration and workflow
1. Stewardship checkpoints
- Barcode-verify valsartan strength (25 / 50 / 100 mg) and combination product name before every pass
- Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change
- Screen admission medication lists for OTC renal stressors undocumented preadmission NSAID aspirin stacks
2. High-alert designation
Not universally classified institutional high-alertValsartan is not universally classified as an institutional high-alert medication, but nurses should treat pregnancy exposure, angioedema, hyperkalemia, renal deterioration, and hypotension as high-stakes safety events.
3. Hold and question cues
- New lip or tongue swelling or voice change—hold valsartan and treat as airway emergency until cleared
- Creatinine jump ≥30% clinician-defined institution thresholds after RAS initiation mandates hold clarification per policy
- Patient purchased OTC anti-inflammatory pills without informing team—coordinate pause teaching prescriber review
Teach-back prompts
- “Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face lip tongue airway difficulty emergency activation.)
- “Why should potassium salt substitutes worry your heart team?” (Patient links ARB therapy to hyperkalemia risk.)
Pharmacist: Dual RAS therapy review, potassium binder coordination, NSAID courses, suspension compounding, breastfeeding risk–benefit, aliskiren interaction checks.
Prescriber / cardiology: Heart failure and post-MI titration, resistant hypertension, pregnancy planning, hyperkalemia management, renal artery stenosis suspicion, angioedema after ACE inhibitor.
🧠 Quick mental checklist
- Pregnancy ruled out or already escalated if suspected?
- Potassium and creatinine trends acceptable for today’s dose?
- Volume status fair after diuretics, vomiting, or poor intake?
- Any lip, tongue, or throat swelling since last dose?
- NSAIDs, potassium supplements, or duplicate RAS drugs on the MAR?
Valsartan NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for valsartan: use the case tabs (MAR, Labs, History, Nursing notes) for priority actions, SATA cue recognition, potassium/creatinine trend SATA, urgency matrix sorting, pregnancy teaching MCQ, and overdose cloze—focused on hyperkalemia, fetal toxicity, and hypotension without a labeled antidote.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Diovan (valsartan) 160 mg PO daily at 0900—due now (day 5 of therapy)
- Furosemide 40 mg PO daily at 0700
- Spironolactone 25 mg PO daily at 0800
- Aspirin 81 mg PO daily; metoprolol 25 mg PO twice daily
- Potassium: 4.6 → 5.2 → 5.9 mEq/L (repeat drawn)
- Serum creatinine: 1.0 → 1.4 → 1.8 mg/dL
- eGFR ~42 mL/min/1.73 m²
- BMP otherwise: sodium 138, glucose 142 mg/dL
- 24-h intake ~1.2 L PO; output ~650 mL urine (concentrated)
- Weight up 1.8 kg since admission; mild pitting edema ankles
- BP trend: 128/78 → 112/68 → 98/58 mm Hg sitting this morning
- Patient reports lightheadedness standing—orthostatics not yet repeated
- Heart failure admission; valsartan started after diuretic uptitration—no angioedema history
- Patient ate banana and used salt substitute at lunch (teaching gap documented)
- Clinic called: repeat β-hCG positive—patient still has valsartan tablets at bedside
- Reports skipped home pregnancy test last month because “BP pills are not related to pregnancy”
Answer key & rationale
Frequently asked questions
Why is hyperkalemia the top electrolyte concern with valsartan?
Angiotensin II receptor blockade reduces aldosterone-driven potassium excretion. Diovan labeling directs periodic serum potassium monitoring and dose reduction or discontinuation when hyperkalemia develops, especially with potassium supplements, potassium-sparing diuretics, or other drugs that raise potassium.
What should nurses do if pregnancy is detected on valsartan?
Discontinue valsartan as soon as possible. The boxed warning states drugs acting on the renin-angiotensin system during the second and third trimesters can reduce fetal renal function and cause fetal and neonatal morbidity and death, including oligohydramnios-related complications and neonatal renal failure.
Can valsartan cause angioedema like ACE inhibitors?
Yes, although less common than with ACE inhibitors. Diovan postmarketing data report rare angioedema involving the face, lips, tongue, or larynx—including airway obstruction—and some patients had prior ACE inhibitor angioedema. Discontinue immediately and escalate airway care when breathing is threatened.
Is there an antidote for valsartan overdose?
Limited human overdosage data exist. Labeling states the most likely manifestation is hypotension and tachycardia, with possible bradycardia from vagal stimulation; treat with supportive care. Neither valsartan nor its active metabolite can be removed by hemodialysis per prescribing information.
Can patients breastfeed while taking valsartan?
It is not known whether valsartan is excreted in human milk; significant levels were present in rat milk. Diovan labeling advises choosing either breastfeeding or valsartan—not both—after weighing drug importance to the mother. Use LactMed and prescriber guidance for individualized counselling.
What starting dose is used for adult hypertension on valsartan?
For adults who are not volume-depleted, the recommended starting dose is 80 mg or 160 mg once daily, with a maximum of 320 mg once daily. Correct volume or salt depletion before administration when patients are on diuretics.
References
-
U.S. National Library of Medicine. Valsartan tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8fcd4c2-8baa-452a-b723-5cb3d8d203a9
-
Drugs and Lactation Database (LactMed). Valsartan. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501629/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.